An overview of cytokine interactions in atherosclerosis and implications for peripheral arterial disease

Vascular Medicine

Volumn 12, Issue 4, 2007, Pages 299-309

  Girn, Hardev Ramandeep Singh ^a   Orsi, N M ^b   Homer Vanniasinkam, S ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

Atherosclerosis; Biomarkers; Cytokines; Interleukins; Peripheral arterial disease

Indexed keywords

AUTACOID; BIOLOGICAL MARKER; CYTOKINE; ETANERCEPT; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; SIMVASTATIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AORTA ANEURYSM; ARTERY DISEASE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BLOOD RHEOLOGY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; CYTOKINE PRODUCTION; DISEASE MARKER; HIGH RISK PATIENT; HUMAN; MEDICAL RESEARCH; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; RISK ASSESSMENT; THROMBOGENICITY;

ATHEROSCLEROSIS; CHEMOKINES; CYTOKINES; HUMANS; INTERFERONS; INTERLEUKINS; PERIPHERAL VASCULAR DISEASES; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTORS; TUMOR NECROSIS FACTORS;

EID: 38449101883     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X07083387     Document Type: Review

References (103)

1. Stary HC, Chandler AB, Glagov S et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994; 89: 2462-78.
2. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation 2004; 110: 738-43.
3. Hirsch AT, Criqui MH, Treat-Jacobson D et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286: 1317-24.
4. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC working group. TransAtlantic Intersociety consensus (TASC). J Vasc Surg 2000; 31: 1-296.
5. Schonbeck U, Sukhova GK, Gerdes N, Libby P. T(H)2 predominant immune responses prevail in human abdominal aortic aneurysm. Am J Pathol 2002; 161: 499-506.
6. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 2006; 17: 699-706.
7. Dinarello CA. Interleukin-1. Cytokine Growth Factor Rev 1997; 8: 253-65.
8. Libby P, Sukhova G, Lee RT, Galis ZS. Cytokines regulate vascular functions related to stability of the atherosclerotic plaque. J Cardiovasc Pharmacol 1995; 25(suppl 2): S9-12.
9. Bresnihan B, Alvaro-Gracia JM, Cobby M et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998; 41: 2196-204.
10. Fiotti N, Giansante C, Ponte E et al. Atherosclerosis and inflammation. Patterns of cytokine regulation in patients with peripheral arterial disease. Atherosclerosis 1999; 145: 51-60.
11. McDermott MM, Guralnik JM, Corsi A et al. Patterns of inflammation associated with peripheral arterial disease: the InCHIANTI study. Am Heart J 2005; 150: 276-81.
12. Zheng H, Fletcher D, Kozak W et al. Resistance to fever induction and impaired acute-phase response in interleukin-1 beta-deficient mice. Immunity 1995; 3: 9-19.
13. Dinarello CA. IL-18: A TH1-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 1999; 103(1 Pt 1): 11-24.
14. Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study. Circulation 2005; 112: 976-83.
15. Oyama J, Shimokawa H, Morita S, Yasui H, Takeshita A. Elevated interleukin-1beta in pericardial fluid of patients with ischemic heart disease. Coron Artery Dis 2001; 12: 567-71.
16. Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma. Circ Res 2002; 90: E34-38.
17. Mallat Z, Corbaz A, Scoazec A et al. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res 2001; 89: E41-45.
18. Elhage R, Jawien J, Rudling M et al. Reduced atherosclerosis in interleukin-18 deficient apolipoprotein E-knockout mice. Cardiovasc Res 2003; 59: 234-40.
19. Mallat Z, Corbaz A, Scoazec A et al. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001; 104: 1598-603.
20. Tiret L, Godefroy T, Lubos E et al. Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 2005; 112: 643-50.
21. Gilardini L, McTernan PG, Girola A et al. Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents. Atherosclerosis 2006; 189: 401-407.
22. Lindholt JS, Shi GP. Chronic inflammation, immune response, and infection in abdominal aortic aneurysms. Eur J Vasc Endovasc Surg 2006; 31: 453-63.
23. Wan YY, Flavell RA. The roles for cytokines in the generation and maintenance of regulatory T cells. Immunol Rev 2006; 212:114-30.
24. Vadiveloo PK, Stanton HR, Cochran FW, Hamilton JA. Interleukin-4 inhibits human smooth muscle cell proliferation. Artery 1994; 21: 161-81.
25. Khew-Goodall Y, Wadham C, Stein BN, Gamble JR, Vadas MA. Stat6 activation is essential for interleukin-4 induction of P-selectin transcription in human umbilical vein endothelial cells. Arterioscler Thromb Vasc Biol 1999; 19: 1421-29.
26. Shimizu K, Libby P, Mitchell RN. Local cytokine environments drive aneurysm formation in allografted aortas. Trends Cardiovasc Med 2005; 15: 142-48.
27. Morita Y, Gupta R, Seidl KM, McDonagh KT, Fox DA. Cytokine production by dendritic cells genetically engineered to express IL-4: induction of Th2 responses and differential regulation of IL-12 and IL-23 synthesis. J Gene Med 2005; 7: 869-77.
28. Szodoray P, Timar O, Veres K et al. TH1/TH2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines - immunological alterations in acute coronary syndrome and stable coronary artery disease. Scand J Immunol 2006; 64: 336-44.
29. Ishibashi T, Yokoyama K, Shindo J et al. Potent cholesterol-lowering effect by human granulocyte-macrophage colony-stimulating factor in rabbits. Possible implications of enhancement of macrophage functions and an increase in mRNA for VLDL receptor. Arterioscler Thromb 1994; 14: 1534-41.
30. Shindo J, Ishibashi T, Yokoyama K et al. Granulocyte-macrophage colony-stimulating factor prevents the progression of atherosclerosis via changes in the cellular and extracellular composition of atherosclerotic lesions in Watanabe heritable hyperlipidemic rabbits. Circulation 1999; 99: 2150-56.
31. Hamilton JA, Stanley ER, Burgess AW, Shadduck RK. Stimulation of macrophage plasminogen activator activity by colony-stimulating factors. J Cell Physiol 1980; 103: 435-45.
32. Hamilton JA, Anderson GP. GM-CSF biology. Growth Factors 2004; 22: 225-31.
33. Cosio BG, Mann B, Ito K, Jazrawi E, Barnes PJ, Chung KF, Adcock IM. Histone acetylase and deacetylase activity in alveolar macrophages and blood monocytes in asthma. Am J Respir Crit Care Med 2004; 170: 141-47.
34. Seiler C, Pohl T, Wustmann K et al. Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 2001; 104: 2012-17.
35. Van Royen N, Schirmer SH, Atasever B et al. START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease. Circulation 2005; 112: 1040-46.
36. Grundmann S, Hoefer I, Ulusans S et al. Granulocyte-macrophage colony-stimulating factor stimulates arteriogenesis in a pig model of peripheral artery disease using clinically applicable infusion pumps. J Vasc Surg 2006; 43: 1263-69.
37. Namen AE, Lupton S, Hjerrild K et al. Stimulation of B-cell progenitors by cloned murine interleukin-7. Nature 1988; 333: 571-73.
38. Jiang Q, Li WQ, Aiello FB et al. Cell biology of IL-7, a key lymphotrophin. Cytokine Growth Factor Rev 2005; 16: 513-33.
39. Damas JK, Waehre T, Yndestad A et al. Interleukin-7-mediated inflammation in unstable angina: possible role of chemokines and platelets. Circulation 2003; 107: 2670-76.
40. Prunet C, Montange T, Vejux A et al. Multiplexed flow cytometric analyses of pro- and anti-inflammatory cytokines in the culture media of oxysterol-treated human monocytic cells and in the sera of atherosclerotic patients. Cytometry A 2006; 69: 359-73.
41. Nylaende M, Kroese A, Stranden E et al. Markers of vascular inflammation are associated with the extent of atherosclerosis assessed as angiographic score and treadmill walking distances in patients with peripheral arterial occlusive disease. Vasc Med 2006; 11: 21-28.
42. DePalma RG, Hayes VW, May PE et al. Statins and biomarkers in claudicants with peripheral arterial disease: cross-sectional study. Vascular 2006; 14: 193-200.
43. Armitage JD, Lindsey NJ, Homer-Vanniasinkam S. The role of endothelial cell reactive antibodies in peripheral arterial disease. Eur J Vasc Endovasc Surg 2006; 31: 170-75.
44. Libra M, Signorelli SS, Bevelacqua Y et al. Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol 2006; 59:211-15.
45. Allison MA, Criqui MH, McClelland RL et al. The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol 2006; 48: 1190-97.
46. Hoogeveen RC, Morrison A, Boerwinkle E et al. Plasma MCP-1 level and risk for peripheral arterial disease and incident coronary heart disease: Atherosclerosis Risk in Communities study. Atherosclerosis 2005; 183: 301-307.
47. Danielsson P, Truedsson L, Eriksson KF, Norgren L. Inflammatory markers and IL-6 polymorphism in peripheral arterial disease with and without diabetes mellitus. Vasc Med 2005; 10: 191-98.
48. Ziegler S, Kudlacek S, Luger A, Minar E. Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis 2005; 182: 175-80.
49. DePalma RG, Hayes VW, Cafferata HT et al. Cytokine signatures in atherosclerotic claudicants. J Surg Res 2003; 111: 215-21.
50. Silvestro A, Scopacasa F, Ruocco A et al. Inflammatory status and endothelial function in asymptomatic and symptomatic peripheral arterial disease. Vasc Med 2003; 8: 225-32.
51. Testa M, De Ruvo E, Russo A et al. Induction of interleukin-1beta and interleukin-6 gene expression in hypoperfused skeletal muscle of patients with peripheral arterial disease. Ital Heart J 2000; 1: 64-67.
52. Kirk G, Hickman P. McLaren M, Stonebridge PA, Belch JJ. Interleukin-8 (IL-8) may contribute to the activation of neutrophils in patients with peripheral arterial occlusive disease (PAOD). Eur J Vasc Endovasc Surg 1999; 18: 434-38.
53. Haddy N, Sass C, Droesch S et al. IL-6, TNF-alpha and atherosclerosis risk indicators in a healthy family population: the STANISLAS cohort. Atherosclerosis 2003; 170: 277-83.
54. Von der Thusen JH, Kuiper J, van Berkel TJ, Biessen EA. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev 2003; 55: 133-66.
55. Klouche M, Rose-John S, Schmiedt W, Bhakdi S. Enzymatically degraded, nonoxidized LDL induces human vascular smooth muscle cell activation, foam cell transformation, and proliferation. Circulation 2000; 101: 1799-805.
56. Hauer AD, Uyttenhove C, de Vos P et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation 2005; 112: 1054-62.
57. Uyemura K, Demer LL, Castle SC et al. Cross-regulatory roles of interleukin (IL)-12 and IL-10 in atherosclerosis. J Clin Invest 1996; 97: 2130-38.
58. Zhang X, Niessner A, Nakajima T et al. Interleukin 12 induces T-cell recruitment into the atherosclerotic plaque. Circ Res 2006; 98: 524-31.
59. Baidya SG, Zeng QT, Wang X, Guo HP. T helper cell related interleukins and the angiographic morphology in unstable angina. Cytokine 2005; 30: 303-10.
60. Steppich BA, Moog P. Matissek C et al. Cytokine profiles and T cell function in acute coronary syndromes. Atherosclerosis 2007; 190: 443-51.
61. Hochrein H, O'Keeffe M, Luft T et al. Interleukin (IL)-4 is a major regulatory cytokine governing bioactive IL-12 production by mouse and human dendritic cells. J Exp Med 2000; 192: 823-33.
62. Chung HK, Lee IK, Kang H et al. Statin inhibits interferon-gamma-induced expression of intercellular adhesion molecule-1 (ICAM-1) in vascular endothelial and smooth muscle cells. Exp Mol Med 2002; 34: 451-61.
63. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev 2006; 86: 515-81.
64. Buono C, Come CE, Stavrakis G, Maguire GF, Connelly PW, Lichtman AH. Influence of interferon-gamma on the extent and phenotype of diet-induced atherosclerosis in the LDLR-deficient mouse. Arterioscler Thromb Vasc Biol 2003; 23: 454-60.
65. Xiong W, Zhao Y, Prall A, Greiner TC, Baxter BT. Key roles of CD4+ T cells and IFN-gamma in the development of abdominal aortic aneurysms in a routine model. J Immunol 2004; 172: 2607-12.
66. Leon ML, Zuckerman SH. Gamma interferon: a central mediator in atherosclerosis. Inflamm Res. 2005; 54: 395-411.
67. Young JL, Libby P, Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002; 88: 554-67.
68. Harvey EJ, Ramji DP. Interferon-gamma and atherosclerosis: pro- or anti-atherogenic? Cardiovasc Res 2005; 67:11-20.
69. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol 1990; 65: 297-302.
70. Galis ZS, Muszynski M, Sukhova GK, Simon-Morrissey E, Libby P. Enhanced expression of vascular matrix metalloproteinases induced in vitro by cytokines and in regions of human atherosclerotic lesions. Ann N Y Acad Sci 1995; 748: 501-507.
71. Taubman MB, Fallon JT, Schecter AD et al. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost. 1997; 78: 200-204.
72. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 2003; 107: 3133-40.
73. Muller-Ehmsen J, Schwinger RH. TNF and congestive heart failure: therapeutic possibilities. Expert opinion on therapeutic targets. 2004; 8: 203-209.
74. Boisvert WA. Modulation of atherogenesis by chemokines. Trends Cardiovasc Med 2004; 14: 161-65.
75. Shin WS, Szuba A, Rockson SG. The role of chemokines in human cardiovascular pathology: enhanced biological insights. Atherosclerosis 2002; 160: 91-102.
76. Ballantyne CM, Nambi V. Markers of inflammation and their clinical significance. Atheroscler Suppl 2005; 6: 21-29.
77. Leu HB, Wu CC, Wu TC, Lin SJ, Chen JW. Fluvastatin reduces oxidative stress, decreases serum monocyte chemotactic protein-1 level and improves endothelial function in patients with hypercholesterolemia. J Formos Med Assoc 2004; 103: 914-20.
78. Charo IF, Taubman MB. Chemokines in the pathogenesis of vascular disease. Circ Res 2004; 95: 858-66.
79. Ito T, Ikeda U. Inflammatory cytokines and cardiovascular disease. Curr Drug Targets 2003; 2: 257-65.
80. Boisvert WA, Santiago R, Curtiss LK, Terkeltaub RA. A leukocyte homologue of the IL-8 receptor CXCR-2 mediates the accumulation of macrophages in atherosclerotic lesions of LDL receptor-deficient mice. J Clin Invest 1998; 101: 353-63.
81. Yamagishi M, Higashikata T, Ishibashi-Ueda H et al. Sustained upregulation of inflammatory chemokine and its receptor in aneurysmal and occlusive atherosclerotic disease: results from tissue analysis with cDNA macroarray and real-time reverse transcriptional polymerase chain reaction methods. Circ J 2005; 69: 1490-95.
82. Moreau M, Brocheriou I, Petit L, Ninio E, Chapman MJ, Rouis M. Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages: relevance to stability of atherosclerotic plaque. Circulation 1999; 99: 420-26.
83. Martins TB, Anderson JL, Muhlestein JB et al. Risk factor analysis of plasma cytokines in patients with coronary artery disease by a multiplexed fluorescent immunoassay. Am J Clin Pathol 2006; 125: 906-13.
84. Mallat Z, Besnard S, Duriez M et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17-24.
85. Namiki M, Kawashima S, Yamashita T et al. Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice. Atherosclerosis 2004; 172: 21-29.
86. Mallat Z, Heymes C, Ohan J, Faggin E, Leseche G, Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999; 19: 611-16.
87. Terkeltaub RA. IL-10: An 'immunologic scalpel' for atherosclerosis? Arterioscler Thromb Vasc Biol 1999; 19: 2823-25.
88. Pinderski Oslund LJ, Hedrick CC, Olvera T et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 2847-53.
89. Poe JC, Wagner DH Jr, Miller RW, Stout RD, Suttles J. IL-4 and IL-10 modulation of CD40-mediated signaling of monocyte IL-1beta synthesis and rescue from apoptosis. J Immunol 1997; 159: 846-52.
90. Anguera I, Miranda-Guardiola F, Bosch X et al. Elevation of serum levels of the anti-inflammatory cytokine interleukin-10 and decreased risk of coronary events in patients with unstable angina. Am Heart J 2002; 144: 811-17.
91. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 2001; 104: 746-49.
92. Heeschen C, Dimmeler S, Hamm CW et al. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 2003; 107: 2109-14.
93. Davis VA, Persidskaia RN, Baca-Regen LM, Fiotti N, Halloran BG, Baxter BT. Cytokine pattern in aneurysmal and occlusive disease of the aorta. J Surg Res 2001; 101: 152-56.
94. Metcalfe JC, Grainger DJ. Transforming growth factor-beta and the protection from cardiovascular injury hypothesis. Biochem Soc Trans 1995; 23: 403-406.
95. Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol 2004; 24: 399-404.
96. Yamagami S, Yokoo S, Mimura T, Amano S. Effects of TGF-beta2 on immune response-related gene expression profiles in the human corneal endothelium. Invest Ophthalmol Vis Sci 2004; 45: 515-21.
97. Ashcroft GS. Bidirectional regulation of macrophage function by TGF-beta. Microbes Infect 1999; 1: 1275-82.
98. Turner M, Chantry D, Feldmann M. Transforming growth factor beta induces the production of interleukin 6 by human peripheral blood mononuclear cells. Cytokine 1990; 2: 211-16.
99. Kulkarni AB, Huh CG, Becker D et al. Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death. Proc Natl Acad Sci U S A 1993; 90: 770-74.
100. Grainger DJ, Mosedale DE, Metcalfe JC, Bottinger EP. Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. J Cell Sci 2000; 113(Pt 13): 2355-61.
101. Mallat Z, Gojova A, Marchiol-Fournigault C et al. Inhibition of transforming growth factor-beta signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice. Circ Res 2001; 89: 930-34.
102. Lutgens E, Gijbels M, Smook M et al. Transforming growth factor-beta mediates balance between inflammation and fibrosis during plaque progression. Arterioscler Thromb Vasc Biol 2002; 22: 975-82.
103. Erren M, Reinecke H, Junker R et al. Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol 1999; 19: 2355-63.